MedDataX Logo

Ramipril in Rheumatoid Arthritis

NCT00273533 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2008-07-22

No results posted yet for this study

Summary

The present study is designed to evaluate the hypothesis that the Angiotensin-Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Ramipril

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • Ali Shokry · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2006-07-31

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00273533 on ClinicalTrials.gov